Gregory L Weaver insider trades
Open-market stock purchases and sales by Gregory L Weaver, Chief Financial Officer at Altimmune, Inc, from SEC Form 4 filings since Feb 4, 2010.
Track record: 0% of 3 scored buys are up 5% or more since purchase, averaging -29%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jul 31, 2026 | ALT Altimmune, Inc | Bought (not open market) | $4.2K |
| Apr 1, 2026 | ALT Altimmune, Inc | Bought | $31.5K |
| Mar 6, 2026 | ALT Altimmune, Inc | Bought | $17.7K |
| Feb 26, 2026 | ALT Altimmune, Inc | Bought (not open market) | — |
| Feb 26, 2026 | ALT Altimmune, Inc | Bought (not open market) | — |
| Nov 11, 2025 | ALT Altimmune, Inc | Sold (not open market) | $24.3K |
| Nov 11, 2025 | ALT Altimmune, Inc | Bought (not open market) | — |
Companies traded
- ALT Altimmune, Inc: 3 buys, last Jul 31, 2026
- ATOS Atossa Therapeutics, Inc: 2 buys, 2 sales, last Nov 15, 2023
- ATAI ATAI Life Sciences NV: 1 buy, last Mar 2, 2022
- ELOX Eloxx Pharmaceuticals, Inc: 1 buy, last Mar 15, 2020
- EGLT Egalet Corp: other filings, last May 14, 2018
- SVON Eloxx Pharmaceuticals, Inc: other filings, last Dec 20, 2017
- FCSC Fibrocell Science, Inc: 1 buy, last Jan 17, 2014
- CLSN Celsion Corp: 3 buys, 1 sale, last Mar 19, 2013
- PARD Poniard Pharmaceuticals, Inc: other filings, last Feb 4, 2010